- Design
- Commentary on a population-based observational programme evaluation
- Population
- Infants in Galicia, Spain, given universal nirsevimab
- Primary outcome
- RSV lower respiratory tract infection hospitalisation
- Effect
- Season 1: −85.9% (80.2–90.0); season 2: −55.3% (22.5–74.3)
A commentary in The Lancet Infectious Diseases (13 October) revisits the Galician nirsevimab programme, NIRSE-GAL. Universal infant prophylaxis was associated with 85.9% fewer RSV lower respiratory tract hospitalisations in the first season and 55.3% fewer in the second, when the antibody should have worn off.
The authors propose explanations: lungs spared injury at a vulnerable age, protection concentrated in the most susceptible infants, and avoidance of severe-infection immune reprogramming. They are clear that the second-season finding has not been replicated and rests on the assumption that the children protected in year one would have been those admitted in year two.
The reassuring part is firmer: no sign of enhanced disease or a shift of severe illness to older ages after prophylaxis.
- First-season protection against RSV admission was about 86% in Galicia
- A second-season reduction of about 55% is observational and unconfirmed
- No enhanced disease or age shift was seen after prophylaxis
- Counsel parents on first-season benefit; do not promise second-season protection
Why it matters
If real, the lasting effect would change the cost-benefit sums for national RSV programmes.
Don't overread it
Observational data from one region, interpreted in a commentary — not a trial result.
The statistics, in plain English
The second-season estimate of 55.3% has a wide 95% CI (22.5% to 74.3%), so the true effect could be modest. Population-level comparisons like this can be confounded by changes in RSV circulation from one season to the next.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free